A Phase 2 interventional study of eltrombopag and placebo in Thrombocytopaenia, sponsored by Novartis Pharmaceuticals. Completed at 120 sites in 22 countries. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2017-06-05.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing eltrombopag in Thrombocytopenia — 2 open to participants now, 3 under way, none of them phase 3. eltrombopag · Thrombocytopenia.
Among the 53 studies testing eltrombopag in Thrombocytopenia, this one is the 8th largest by enrollment, is one of 6 that started in 2011, is one of 27 in phase 2, and was the 27th registered.
484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.
Browse Thrombocytopenia studies →2 of the 53 studies testing eltrombopag in Thrombocytopenia are open now, in 2 countries. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 3–99
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 110 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 33 · Phase 3 13 · Phase 4 3
First in 2005; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 162 is above the median of 54 across 336 interventional studies indexed under Thrombocytopenia.
Median enrollment 40 across the 53 interventional studies. Of the 45 that completed or were terminated, 25 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 53 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
10 studies in Thrombocytopenia by Novartis: none open now, none under way, none of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 10 studies in Thrombocytopenia by Novartis, this one is the only one that started in 2011, is one of 3 in phase 2, and was the 5th registered.
Novartis’s Thrombocytopenia studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 53 studies testing eltrombopag in Thrombocytopenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 10 in Thrombocytopenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a worldwide, three-part (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension), multi-center study to evaluate the effect of eltrombopag in subjects with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who have thrombocytopenia due to bone marrow insufficiency from their underlying disease or prior chemotherapy. This objective was assessed by a composite primary endpoint that consists of the following: the proportion of ≥Grade 3 hemorrhagic adverse events, or platelet counts \<10 Gi/L, or platelet transfusions. Patients with MDS or AML and Grade 4 thrombocytopenia due to bone marrow insufficiency from their underlying disease or prior chemotherapy were enrolled in the study. No low or intermediate-1 risk MDS subjects were enrolled in the study. Subjects must have had at least one of the following during the 4 weeks prior to enrolment: platelet count \<10 Gi/L, platelet transfusion, or symptomatic hemorrhagic event. Supportive standard of care (SOC), including hydroxyurea, was allowed as indicated by local practice throughout the study. The study had 3 sequential parts. Subjects who were enrolled in Part 1 (open-label) cannot be enrolled in Part 2 of the study (randomized, double-blind); however, subjects who completed the treatment period for Part 1 or Part 2 (8 and 12 weeks, respectively) continued in Part 3 (extension) if the investigator determined that the subject was receiving clinical benefit on treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 mg daily (50 mg for subjects of East Asian heritage), intrasubject dose escalations to a maximum dose 300 mg (150 mg for subjects of East Asian heritage) are allowed.
Drug: eltrombopag
100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
Drug: eltrombopag
100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
Drug: placebo
100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
Drug: eltrombopag
100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
Also known as: Promacta
100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
Number of Participants With Platelet Response up to Week 8 During Part 1
A participant was considered as a responder if he/she met the following response criteria: a Baseline platelet count \<20 Giga cells per liter (Gi/L) and a post-Baseline increased to \>20 Gi/L and at least 2 times the Baseline value; or a Baseline platelet count \>=20 Gi/L and a post-Baseline absolute platelet count increased to \>=50 Gi/L and at least 2 times the Baseline value. The response criteria was evaluated at each visit. Increase in platelet count observed up to 3 days after a platelet transfusion was not considered as a platelet response. The Part 1 Population was comprised of all participants enrolled into Part 1.
Time frame: From Baseline up to Week 8 during Part 1
Clinically Relevant Thrombocytopenic Events (CRTE) From Week 5 up to Week 12 During Part 2
A participant was considered to have a CRTE at a given assessment if he/she had platelet counts \<10 Gi/L, or platelet transfusions, or \>=Grade 3 hemorrhagic adverse events. CRTEs during Weeks 5 to 12 were compared between treatments using a generalized linear mixed model. Average of weekly proportion of subjects with CRTE during Week 5 to 12 was estimated for each treatment. Intent to Treat (ITT) Population was comprised of all randomized participants during Part 2.
Time frame: From Week 5 up to Week 12 during Part 2
Plasma Eltrombopag Pharmacokinetic Concentration-Time Data - by Visit (Part 1 Subjects)
Time frame: Day 1 to week 8
Plasma Eltrombopag Pharmacokinetic Concentration-Time Data - by Visit (Part 2 Subjects)
Time frame: Day 1 to week 12
Mean Number of Platelet Transfusions
Time frame: Weeks 5 to 12
Hematologic Improvement
Definitions of hematologic improvement for platelets, neutrophils, and hemoglobin were based on modified International Working Group (IWG) consensus criteria.
Time frame: Weeks 5 to 12
Change in Mean Platelet Count
Time frame: Baseline to Week 12
Maximum Duration of Platelet Transfusion Independence
Time frame: Weeks 5 to 12
Number of Participants With Maximum Bleeding Grade According to World Health Organization on Bleeding Scale
Occurrence and severity of bleeding, measured using the WHO Bleeding Scale Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross blood loss; Grade 4=debilitating blood loss.
Time frame: Weeks 5 to 12
Independent Reviewer-Assessed Best Response
Participants were evaluated in accordance with the modified International Working Group (Cheson, 2006). CR: Bone marrow blasts \<5%, Hgb ≥11g/dL, Hematologic Improvement - Platelets (Baseline \<20Gi/L: \>20 Gi/L and 2x baseline; Baseline ≥20 Gi/L: ≥50 Gi/L and 2x baseline), Neutrophils ≥1.0 Gi/L, Peripheral blasts 0%. PR: Bone marrow blasts decreased by ≥50% but \>5%, Peripheral blood as in CR. Marrow CR: Bone marrow blasts \<5% and decrease by ≥50%, Note any Hematologic Improvements, Stable disease: Failure to achieve PR, but no evidence of progression for \>8w, Cytogenetic response: Complete: disappearance of chromosomal abnormality; no new abnormalities Partial: ≥50% reduction of chromosomal abnormality.
Time frame: up to week 12
Independent Reviewer Assessed Disease Progression
Time frame: Up to week 12
Median Overall Survival
Time frame: Up to 13 months
Summary of Health Outcomes
The number of subject with medical resource utilization (MRU) data are reported in this table. MRU included number of emergency room visits, number of home healthcare visits, number of hospitalization days, number of medication or surgery specialist visits, number of procedures inpatient, number of procedures outpatient, number of non-study radiology visits, number of non-study laboratory visits, number of nurse practitioner/physician assistance/nurse visits, number of primary care physician visits, number of telephone consultations.
Time frame: week 12
Functional Assessment of Cancer Therapy (FACT)
The FACT-Th-18 is the most widely used and accepted tool evaluating health-related quality-of-life outcomes in cancer patients with chronically low platelets (where Th designates thrombocytopenia). The entire FACT-Th-18 was used in this trial, which includes the 18-item thrombocytopenia subscale used to assess the impact of symptoms, signs, and functional consequences of thrombocytopenia in MDS and AML subjects. The FACT-Th-18 is a validated and reliable instrument with known psychometric properties. FACT-ThS is an 18 item questionnaire specific to assessing the impact of symptoms, signs, and functional consequences of Thrombocytopenia. ThS score ranges from 0 to 72 with higher the score, the better the QoL. FACT G total score moves from 0 to 108 where higher the score, the better the HRQL. FACT-Th Total Score is calculated by adding the FACT-ThS and FACT-G score. Total score ranges from 0 to 180 and again, higher the score, the better the HRQL.
Time frame: Change from baseline, up to week 12
EQ-5D Utility Score Analysis
EuroQoL Five Dimensions Questionnaire (EQ-5D) is a standardized generic preference based health related quality of life instrument. It records how one's health is "today" and consists of a descriptive system. The Descriptive system is Comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem(s) and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life. EQ-ED is a score.
Time frame: Change from baseline, up to week 12
Part 1, 17 subjects received open-label eltrombopag. Part 2, 145 subjects were randomized to receive eltrombopag plus SOC (N=98) or placebo plus SOC (N=47). Part 3, 59 subjects from Part 2 entered Part 3. SOC was allowed as needed throughout the study. Subjects could receive disease-modifying therapy as needed.
| Milestone | Part 1: Eltrombopag | Part 2: Placebo | Part 2: Eltrombopag | Part 3: Eltrombopag |
|---|---|---|---|---|
| Started | 17 | 0 | 0 | 0 |
| Completed | 11 | 0 | 0 | 0 |
| Not completed | 6 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Milestone | Part 1: Eltrombopag | Part 2: Placebo | Part 2: Eltrombopag | Part 3: Eltrombopag |
|---|---|---|---|---|
| Started | 0 | 47 | 98 | 0 |
| Completed | 0 | 27 | 43 | 0 |
| Not completed | 0 | 20 | 55 | 0 |
| Withdrew: Physician decision | 0 | 8 | 17 | 0 |
| Withdrew: Withdrawal by subject | 0 | 4 | 5 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 7 | 31 | 0 |
| Withdrew: Not treated | 0 | 0 | 1 | 0 |
| Milestone | Part 1: Eltrombopag | Part 2: Placebo | Part 2: Eltrombopag | Part 3: Eltrombopag |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 59 |
| Completed | 0 | 0 | 0 | 27 |
| Not completed | 0 | 0 | 0 | 32 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 13 |
| Withdrew: Physician decision | 0 | 0 | 0 | 14 |
A participant was considered as a responder if he/she met the following response criteria: a Baseline platelet count \<20 Giga cells per liter (Gi/L) and a post-Baseline increased to \>20 Gi/L and at least 2 times the Baseline value; or a Baseline platelet count \>=20 Gi/L and a post-Baseline absolute platelet count increased to \>=50 Gi/L and at least 2 times the Baseline value. The response criteria was evaluated at each visit. Increase in platelet count observed up to 3 days after a platelet transfusion was not considered as a platelet response. The Part 1 Population was comprised of all participants enrolled into Part 1.
| Participants | Part 1: Eltrombopag |
|---|---|
| Number of Participants With Platelet Response up to Week 8 During Part 1 | 4 |
A participant was considered to have a CRTE at a given assessment if he/she had platelet counts \<10 Gi/L, or platelet transfusions, or \>=Grade 3 hemorrhagic adverse events. CRTEs during Weeks 5 to 12 were compared between treatments using a generalized linear mixed model. Average of weekly proportion of subjects with CRTE during Week 5 to 12 was estimated for each treatment. Intent to Treat (ITT) Population was comprised of all randomized participants during Part 2.
| percentages of participants | Part 2: Placebo | Part 2: Eltrombopag |
|---|---|---|
| Clinically Relevant Thrombocytopenic Events (CRTE) From Week 5 up to Week 12 During Part 2 | 69 (57 to 80) | 54 (43 to 64) |
| ug/mL | Part 1: Eltrombopag |
|---|---|
| Baseline/day 1 (Pre-dose PK) | 0 ± 0 |
| Day8 week 1 (Pre-dose PK) | 7.7 ± 3.96 |
| Day15 week 2 (Pre-dose PK) | 7.2 ± 5.17 |
| Day22 week 3 (Pre-dose PK) | 14.3 ± 10.63 |
| Day29 week 3 (2-6hrs post-dose PK) | 20.8 ± 14.98 |
| Day36 week 5 (Pre-dose PK) | 20.2 ± 16.37 |
| Day43 week6 (2-6hrs post-dose PK) | 41.2 ± 32.56 |
| Day50 week 7 (Pre-dose PK) | 30.4 ± 27.95 |
| Day57 week 8 (2-6hrs post-dose PK) | 30.1 ± 18.99 |
| ug/mL | Part 2: Eltrombopag |
|---|---|
| Baseline/day 1 (Pre-dose PK) | 0 ± 0 |
| Day15 week 2 (Pre-dose PK) | 10.1 ± 5.54 |
| Day22 week 3 (2-6hrs post-dose PK) | 24.0 ± 14.6 |
| Day29 week 4 (Pre-dose PK) | 20.2 ± 13.61 |
| Day43 week 6 (Pre-dose PK) | 29.0 ± 18.13 |
| Day50 week 7 (2-6hrs post-dose PK) | 42.9 ± 22.37 |
| Day57 week8 (Pre-dose PK) | 36.3 ± 20.91 |
| Day71 week 10 (Pre-dose PK) | 33.5 ± 20.40 |
| Day78 week 11 (2-6hrs post-dose PK) | 41.2 ± 24.91 |
| Day85 week12 (Pre-dose PK) | 30.7 ± 18.03 |
| Number of platelet transfusions | Part 2: Eltrombopag | Part 2: Placebo |
|---|---|---|
| Mean Number of Platelet Transfusions | 18.8 ± 18.60 | 15.7 ± 20.36 |
Definitions of hematologic improvement for platelets, neutrophils, and hemoglobin were based on modified International Working Group (IWG) consensus criteria.
| Number of subjects | Part 2: Eltrombopag | Part 2: Placebo |
|---|---|---|
| Any Improvement | 10 | 4 |
| Platelets | 8 | 2 |
| Neutrophils | 4 | 4 |
| Hemoglobin | 0 | 0 |
| Platelets and neutrophils | 2 | 2 |
| Platelets and hemoglobin | 0 | 0 |
| Platelets, hemoglobin and neutrophils | 0 | 0 |
| Neutrophils and hemoglobin | 0 | 0 |
| Gi/L | Part 2: Eltrombopag | Part 2: Placebo |
|---|---|---|
| Day8 week1 | 3.36 ± 11.795 | 1.66 ± 6.249 |
| Day15 week2 | 10.41 ± 60.225 | 3.06 ± 9.675 |
| Day22 week3 | 6.23 ± 22.872 | 2.13 ± 9.258 |
| Day29 week4 | 5.63 ± 17.582 | 2.44 ± 11.215 |
| Day36 week5 | 8.58 ± 22.504 | 5.9 ± 16.000 |
| Day43 week6 | 8.64 ± 19.779 | 5.93 ± 21.960 |
| Day50 week7 | 9.91 ± 25.561 | 6.74 ± 31.074 |
| Day57 week8 | 9.67 ± 23.243 | 7.84 ± 34.213 |
| Day64 week9 | 12.84 ± 27.272 | 6.75 ± 31.709 |
| Day71 week10 | 15.97 ± 33.866 | 6.23 ± 30.941 |
| Day78 week11 | 14.42 ± 36.901 | 6.92 ± 26.906 |
| Day 85 week12 | 9.06 ± 28.259 | 4.85 ± 26.219 |
| maximum duration of platelet transfusion | Part 2: Eltrombopag | Part 2: Placebo |
|---|---|---|
| Maximum Duration of Platelet Transfusion Independence | 26.3 ± 21.47 | 25.4 ± 19.70 |
Occurrence and severity of bleeding, measured using the WHO Bleeding Scale Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross blood loss; Grade 4=debilitating blood loss.
| Number of subjects | Part 2: Eltrombopag | Part 2: Placebo |
|---|---|---|
| Grade 0 (no bleeding) | 15 | 4 |
| Grade 1 (petechiae) | 31 | 22 |
| Grade 2 (mild blood loss) | 41 | 14 |
| Grade 3 (gross blood loss) | 5 | 3 |
| Grade 4 (debilitating blood loss) | 1 | 3 |
| Grades 0 - 1 | 46 | 26 |
| Grades 1 - 4 | 78 | 42 |
| Grades 2 - 4 | 47 | 20 |
Participants were evaluated in accordance with the modified International Working Group (Cheson, 2006). CR: Bone marrow blasts \<5%, Hgb ≥11g/dL, Hematologic Improvement - Platelets (Baseline \<20Gi/L: \>20 Gi/L and 2x baseline; Baseline ≥20 Gi/L: ≥50 Gi/L and 2x baseline), Neutrophils ≥1.0 Gi/L, Peripheral blasts 0%. PR: Bone marrow blasts decreased by ≥50% but \>5%, Peripheral blood as in CR. Marrow CR: Bone marrow blasts \<5% and decrease by ≥50%, Note any Hematologic Improvements, Stable disease: Failure to achieve PR, but no evidence of progression for \>8w, Cytogenetic response: Complete: disappearance of chromosomal abnormality; no new abnormalities Partial: ≥50% reduction of chromosomal abnormality.
| Number of subjects | Part 2: Eltrombopag | Part 2: Placebo |
|---|---|---|
| Responder | 1 | 1 |
| Complete response (CR) | 0 | 0 |
| Morphologic CR | 0 | 1 |
| Morphologic leukemia-free state | 0 | 0 |
| Marrow CR | 1 | 0 |
| Cytogenetic CR | 0 | 0 |
| Molecular CR | 0 | 0 |
| Non-responder | 97 | 46 |
| Partial response | 0 | 0 |
| Stable disease (non-responder) | 18 | 10 |
| Progressive disease (non-responder) | 41 | 28 |
| Not evaluable (non-responder) | 36 | 8 |
| Missing (non-responder) | 2 | 0 |
| Number of subjects | Part 2: Eltrombopag | Part 2: Placebo |
|---|---|---|
| Disease progression | 61 ± 21.47 | 36 ± 19.70 |
| No disease progression | 12 | 6 |
| Not evaluable | 23 | 5 |
| Missing | 2 | 0 |
| Months | Part 2: Eltrombopag | Part 2: Placebo |
|---|---|---|
| Median Overall Survival | 4.27 (2.96 to 7.59) | 4.6 (3.29 to 7.82) |
The number of subject with medical resource utilization (MRU) data are reported in this table. MRU included number of emergency room visits, number of home healthcare visits, number of hospitalization days, number of medication or surgery specialist visits, number of procedures inpatient, number of procedures outpatient, number of non-study radiology visits, number of non-study laboratory visits, number of nurse practitioner/physician assistance/nurse visits, number of primary care physician visits, number of telephone consultations.
| Subject with Events | Part 2: Eltrombopag | Part 2: Placebo |
|---|---|---|
| Number of emergency room visits (n=17, n=10) | 1 | 0 |
| Number of home healthcare visits (n=17, n=10) | 2 | 1 |
| Number of hospitalization days (n=17, n=10) | 5 | 4 |
| Number of med/surg specialist visits (n=17, n=10) | 1 | 3 |
| Number of procedures inpatient (n=17, n=10) | 2 | 1 |
| Number of procedures outpatient (n=17, n=10) | 1 | 1 |
| Number of non-study radiology visits (n=2, n=2) | 2 | 2 |
| Number of nurse prac/pa/nurse visits (n=17, n=10) | 5 | 3 |
| Number of primary care physician visits (n=17,10) | 7 | 1 |
| Number of telephone consultations (n=17, n=10) | 1 | 0 |
| Number of non-study laboratory visits (n=17, n=10) | 8 | 6 |
The FACT-Th-18 is the most widely used and accepted tool evaluating health-related quality-of-life outcomes in cancer patients with chronically low platelets (where Th designates thrombocytopenia). The entire FACT-Th-18 was used in this trial, which includes the 18-item thrombocytopenia subscale used to assess the impact of symptoms, signs, and functional consequences of thrombocytopenia in MDS and AML subjects. The FACT-Th-18 is a validated and reliable instrument with known psychometric properties. FACT-ThS is an 18 item questionnaire specific to assessing the impact of symptoms, signs, and functional consequences of Thrombocytopenia. ThS score ranges from 0 to 72 with higher the score, the better the QoL. FACT G total score moves from 0 to 108 where higher the score, the better the HRQL. FACT-Th Total Score is calculated by adding the FACT-ThS and FACT-G score. Total score ranges from 0 to 180 and again, higher the score, the better the HRQL.
| Adjusted mean change from baseline | Part 2: Eltrombopag | Part 2: Placebo |
|---|---|---|
| FACTG week 5 (n=61. n=34) | -0.79 ± 1.64 | -3.15 ± 2.19 |
| FACTG week 9 (n=46. n=28) | -4.83 ± 1.82 | -2.76 ± 2.34 |
| FACTG week12 (n=37. n=26) | -3.38 ± 1.94 | -4.17 ± 2.39 |
| FACTHTOI week 5 (n=61, n=34) | 0.91 ± 2.04 | -2.28 ± 2.74 |
| FACTHTOI week 9 (n=46, n=28) | -1.69 ± 2.24 | 0.19 ± 2.89 |
| FACTHTOI week 12 (n=37, n=26) | -0.26 ± 2.37 | -1.56 ± 2.95 |
EuroQoL Five Dimensions Questionnaire (EQ-5D) is a standardized generic preference based health related quality of life instrument. It records how one's health is "today" and consists of a descriptive system. The Descriptive system is Comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem(s) and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life. EQ-ED is a score.
| Adjusted mean change from baseline | Part 2: Eltrombopag | Part 2: Placebo |
|---|---|---|
| Week 5 (n=55. n=34) | -0.01 ± 0.04 | -0.15 ± 0.05 |
| Week 9 (n=43. n=27) | -0.08 ± 0.04 | -0.06 ± 0.05 |
| Week 12 (n=36. n=26) | -0.09 ± 0.05 | -0.11 ± 0.05 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag, Part 1 Subjects | — | 9/17 (52.9%) | 17/17 (100%) |
| Eltrombopag, Part 2 Plus 1 Day From Part 2 Subjects | — | 56/97 (57.7%) | 89/97 (91.8%) |
| Placebo, Part 2 Plus 1 Day From Part 2 Subjects | — | 32/47 (68.1%) | 44/47 (93.6%) |
| Eltrombopag, Part 3 Plus 30 Days From Part 2 Subjects | — | 39/59 (66.1%) | 54/59 (91.5%) |
| Event | Eltrombopag, Part 1 Subjects | Eltrombopag, Part 2 Plus 1 Day From Part 2 Subjects | Placebo, Part 2 Plus 1 Day From Part 2 Subjects | Eltrombopag, Part 3 Plus 30 Days From Part 2 Subjects |
|---|---|---|---|---|
| SepsisInfections and infestations | 4/17 | 8/97 | 5/47 | 6/59 |
| PneumoniaInfections and infestations | 1/17 | 14/97 | 5/47 | 10/59 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/17 | 7/97 | 7/47 | 6/59 |
| PyrexiaGeneral disorders | 2/17 | 7/97 | 6/47 | 7/59 |
| Septic shockInfections and infestations | 2/17 | 1/97 | 1/47 | 3/59 |
| Urinary tract infectionInfections and infestations | 0/17 | 3/97 | 1/47 | 5/59 |
| BronchitisInfections and infestations | 0/17 | 0/97 | 0/47 | 4/59 |
| DiarrhoeaGastrointestinal disorders | 0/17 | 1/97 | 3/47 | 1/59 |
| Haemolytic anaemiaBlood and lymphatic system disorders | 1/17 | 0/97 | 0/47 | 0/59 |
| Abdominal painGastrointestinal disorders | 1/17 | 2/97 | 0/47 | 0/59 |
| Event | Eltrombopag, Part 1 Subjects | Eltrombopag, Part 2 Plus 1 Day From Part 2 Subjects | Placebo, Part 2 Plus 1 Day From Part 2 Subjects | Eltrombopag, Part 3 Plus 30 Days From Part 2 Subjects |
|---|---|---|---|---|
| PetechiaeSkin and subcutaneous tissue disorders | 6/17 | 41/97 | 11/47 | 8/59 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 5/17 | 27/97 | 11/47 | 12/59 |
| NauseaGastrointestinal disorders | 1/17 | 13/97 | 8/47 | 14/59 |
| FatigueGeneral disorders | 1/17 | 23/97 | 3/47 | 9/59 |
| DiarrhoeaGastrointestinal disorders | 4/17 | 20/97 | 5/47 | 11/59 |
| PyrexiaGeneral disorders | 4/17 | 18/97 | 10/47 | 12/59 |
| PneumoniaInfections and infestations | 4/17 | 3/97 | 1/47 | 2/59 |
| HaematomaVascular disorders | 0/17 | 7/97 | 9/47 | 9/59 |
| AnaemiaBlood and lymphatic system disorders | 3/17 | 8/97 | 2/47 | 2/59 |
| ConstipationGastrointestinal disorders | 3/17 | 12/97 | 0/47 | 7/59 |
Part 3, 59 subjects from Part 2 entered Part 3 (23 of 47 subjects in the placebo group in Part 2 and 36 of 98 subjects in the eltrombopag group in Part 2). All subjects who entered Part 3 received treatment with eltrombopag. SOC was allowed as needed throughout the study. Subjects could receive disease-modifying therapy as needed.
| Age, Continuous(Years) | Part 1: Eltrombopag | Part 2: Placebo | Part 2: Eltrombopag | Total |
|---|---|---|---|---|
| Mean | 71.5 ± 10.78 | 70.6 ± 10.72 | 72.3 ± 8.94 | 71.8 ± 9.56 |
| Sex: Female, Male(Participants) | Part 1: Eltrombopag | Part 2: Placebo | Part 2: Eltrombopag | Total |
|---|---|---|---|---|
| Female | 7 | 16 | 32 | 55 |
| Male | 10 | 31 | 66 | 107 |
| Race/Ethnicity, Customized(Participants) | Part 1: Eltrombopag | Part 2: Placebo | Part 2: Eltrombopag | Total |
|---|---|---|---|---|
| African American/African Heritage | 0 | 0 | 1 | 1 |
| Asian - East Asian Heritage | 3 | 5 | 9 | 17 |
| Asian - South East Asian Heritage | 0 | 2 | 2 | 4 |
| White - Arabic/North African Heritage | 0 | 1 | 5 | 6 |
| White - White/Caucasian/European Heritage | 14 | 39 | 81 | 134 |
Showing the first 100 of 120 sites across 22 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2011, a primary completion of Mar 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag